BioSpace News Archive

Business

SCYNEXIS Reports Third Quarter 2017 Financial Results and Provides Company Update

SCYNEXIS today reported financial results for the quarter ended September 30, 2017, and provided an update on recent operational and clinical developments.

November 7, 2017
·
12 min read
Business

Inogen Announces Record Third Quarter 2017 Financial Results

Record total revenue of $69.0 million, up 26.8% over the same period in 2016.

November 7, 2017
·
18 min read
Business

Ignyta Announces Third Quarter 2017 Company Highlights and Financial Results

For the third quarter of 2017, net loss was $28.6 million, or $0.51 per share, compared with $23.3 million, or $0.56 per share, for the third quarter of 2016.

November 7, 2017
·
11 min read
Business

Alnylam Pharmaceuticals Reports Third Quarter 2017 Financial Results and Highlights Recent Period Activity

At September 30, 2017, Alnylam had cash, cash equivalents and fixed income marketable securities, and restricted investments of $1.15 billion, as compared to $1.09 billion at December 31, 2016.

November 7, 2017
·
22 min read
Business

Ocular Therapeutix Reports Third Quarter 2017 Financial Results and Provides Corporate Update

As of September 30, 2017, cash and cash equivalents totaled $51.2 million.

November 7, 2017
·
13 min read
Business

Endologix Reports Third Quarter 2017 Financial Results

Global revenue in the third quarter of 2017 was $46.0 million, an 11.8% decrease from $52.1 million in the third quarter of 2016.

November 7, 2017
·
13 min read
Business

Glaukos Corporation Announces Third Quarter 2017 Financial Results

Net sales rose 37% in the third quarter of 2017 to $40.4 million, compared to $29.6 million in the same period in 2016.

November 7, 2017
·
9 min read
Business

Corindus Vascular Robotics Reports Third Quarter 2017 Results

Revenue for the third quarter of 2017 was $2.4 million compared to $0.7 million for the same period in the prior year.

November 7, 2017
·
9 min read
Business

ACADIA Pharmaceuticals Reports Third Quarter 2017 Financial Results

Net product sales of NUPLAZID, which was first made available for prescription starting in May 2016, were $35.6 million for the three months ended September 30, 2017 compared to $5.3 million for the three months ended September 30, 2016.

November 7, 2017
·
13 min read
Business

eClinicalHealth Announces the Appointment of Tim Kvanvig as Head of the Company’s Strategic Initiatives

Tim has served in senior management roles leading global information technology organizations at GSK and in Oracle’s life science industry group.

November 7, 2017
·
1 min read